REGENERON AND ALNYLAM ANNOUNCE BROAD COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE RNAI THERAPEUTICS FOCUSED ON OCULAR AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY) announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range…

View More REGENERON AND ALNYLAM ANNOUNCE BROAD COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE RNAI THERAPEUTICS FOCUSED ON OCULAR AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES